Kivenul (Ibuprofen, Paracetamol)

Ibuprofen blocks cyclooxygenase enzymes, lowering peripheral prostaglandin production, which reduces pain and inflammation. Paracetamol acts centrally to inhibit prostaglandin synthesis in the brain, providing antipyretic and analgesic effects. Together they offer synergistic symptom control.

The appropriate dose of Kivenul is determined by a qualified prescriber based on the patient’s age, weight, clinical condition, and response to therapy. Patients should follow the specific dosing instructions provided by their healthcare professional.

Safety of Kivenul in pregnancy or lactation has not been fully established. Healthcare providers should evaluate the risk‑benefit profile for each individual, and use the medication only if clearly needed and prescribed by a qualified professional.

To request Kivenul, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and necessary import documentation.

Kivenul combines an NSAID (ibuprofen) with a centrally acting analgesic (paracetamol), offering broader pain and fever control than either agent alone. Compared with single‑ingredient products, it may provide enhanced efficacy at lower individual doses, but the safety profile must be considered.

Kivenul should be stored at ambient temperature, below 25 °C, in its original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in humid or excessively hot environments.

Kivenul is taken orally, usually with a full glass of water. It can be taken with or without food, but taking it with food may reduce gastrointestinal discomfort. Follow the prescriber’s instructions regarding timing and frequency.

Serious risks include gastrointestinal bleeding or ulcer perforation, severe skin reactions such as Stevens‑Johnson syndrome, hepatic injury, acute renal impairment, and anaphylaxis. Patients should seek immediate medical attention if they experience signs of these conditions.

Kivenul should be avoided by individuals with known hypersensitivity to ibuprofen, paracetamol, or any excipients, those with active peptic ulcer disease, severe liver or kidney dysfunction, uncontrolled hypertension, and patients on anticoagulant therapy unless specifically advised by a healthcare professional.